Physician profile
Bart K Gershenbaum
NPI 1043237514
$324.82
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $58.70 · 2021: $151.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $70.33 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.71 | 2019 | |
| Orexo US, INC. | $59.84 | 2020-2021 | |
| Virtus Pharmaceuticals LLC | $40.26 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.84 | 2019 | |
| Redhill Biopharma INC. | $19.71 | 2021 | |
| Forte Bio-Pharma LLC | $14.98 | 2020-2021 | |
| Amgen INC. | $14.91 | 2021 | |
| Biodelivery Sciences International, INC. | $14.24 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bart Gershenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.